Adaptive Biotechnologies Corporation (ADPT)
$
15.2
-0.85 (-5.59%)
Key metrics
Financial statements
Free cash flow per share
-0.3289
Market cap
2.3 Billion
Price to sales ratio
8.3780
Debt to equity
1.2824
Current ratio
3.3385
Income quality
0.8077
Average inventory
9.9 Million
ROE
-0.3000
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for diagnosing and treating various diseases. The company reported selling, general, and administrative expenses of $167,272,000.00 indicating its operational overhead costs. The operating expenses amount to $262,740,000.00 encompassing various operational costs incurred. With an operating income ratio of -0.21 the company's operational profitability margin is understood in the context of its overall financial health. Additionally, the EBITDA ratio is -0.11 highlighting the company's operational efficiency and its ability to generate earnings before interest, taxes, depreciation, and amortization. Furthermore, the company reported depreciation and amortization expenses of $17,833,000.00 reflecting the wear and tear of its assets in its financial statements. Adaptive Biotechnologies continues to innovate with products such as immunoSEQ and clonoSEQ which serve critical roles in the life sciences research and clinical diagnostics sectors, and its operational effectiveness is vital for its sustained development. The stock is affordable at $13.36 suitable for budget-conscious investors looking for opportunities in the market. The stock has a high average trading volume of 2,399,796.00 indicating strong liquidity that can attract a diverse range of investors. With a market capitalization of $2,320,508,000.00 the company is classified as a small-cap player, a designation that often entails a dynamic growth profile. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape through its innovative immune medicine platform. Additionally, it belongs to the Healthcare sector, driving innovation and growth in the field of health and biotechnology. As it continues to expand its offerings and collaborations with entities like Genentech and Microsoft, Adaptive Biotechnologies positions itself strategically for future advancements in disease diagnostics and treatment options.
Is Adaptive Biotechnologies Corporation (ADPT) a good investment?
Investing in Adaptive Biotechnologies Corporation (ADPT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Adaptive Biotechnologies Corporation (ADPT)'s stock forecast?
Analysts predict Adaptive Biotechnologies Corporation stock to fluctuate between $6.26 (low) and $20.76 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Adaptive Biotechnologies Corporation's market capitalization?
As of 2026-02-20, Adaptive Biotechnologies Corporation's market cap is $2,320,508,000, based on 152,665,000 outstanding shares.
How does Adaptive Biotechnologies Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Adaptive Biotechnologies Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Adaptive Biotechnologies Corporation (ADPT) stock?
To buy Adaptive Biotechnologies Corporation (ADPT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ADPT. Place an order (Market, Limit, etc.).
What is the best time to invest in Adaptive Biotechnologies Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Adaptive Biotechnologies Corporation perform in the last earnings report?
Revenue: $276,976,000 | EPS: -$0.39 | Growth: -63.89%.
Where can I find Adaptive Biotechnologies Corporation's investor relations reports?
Visit https://www.adaptivebiotech.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Adaptive Biotechnologies Corporation?
You can explore historical data from here
What is the all-time high and low for Adaptive Biotechnologies Corporation stock?
All-time high: $40 (2021-09-07) | All-time low: $2.28 (2024-04-19).
What are the key trends affecting Adaptive Biotechnologies Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
Allianz Asset Management GmbH boosted its position in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 305.8% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 321,774 shares of the company's stock after acquiring an additional 242,474 shares during the quarter. Allianz Asset
seekingalpha.com
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
zacks.com
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.23 per share a year ago.
seekingalpha.com
Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
globenewswire.com
SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024.
globenewswire.com
SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced Dr. Harlan Robins, Chief Scientific Officer and Co-Founder and Susan Bobulsky, Chief Commercial Officer, MRD will be participating in a Jefferies fireside chat to discuss Minimal Residual Disease (MRD) in Hematology/Oncology with deep dive into the clonoSEQ assay technology. The call will take place on Thursday, December 11, 2025, from 2:00 p.m. to 3:00 p.m. Eastern Time. Interested parties may reach out to their Jefferies sales representative for details.
zacks.com
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.22 per share a year ago.
zacks.com
Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
See all news
